RBC keeps target at GBp 1,975 for GSK stock ahead of results

Published on 10/14/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC keeps a GBp 1,975 target ahead of GSK's October 28 results. GSK stock trades at EUR 20.83 on October 14, 2026.

Analyst view before results

RBC maintained a Sector Perform rating and a GBp 1,975 target on October 13, 2026.
GSK reported GBP 8.41 billion in second-quarter revenue for the quarter ended June 30, 2026.
GSK stock trades at EUR 20.83 at 1:37 p.m. CEST at Lang & Schwarz on October 14, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) is heading toward its third-quarter results with RBC Capital Markets maintaining a GBp 1,975 target and Sector Perform rating on October 13, 2026. According to Yahoo Finance, RBC expects vaccine pressure to be offset by HIV and respiratory medicines.

RBC sees a balanced quarter

RBC forecasts third-quarter revenue of GBP 8.82 billion against GBP 8.89 billion consensus, a difference of minus 0.79 percent. Its core earnings-per-share forecast is 50.8 pence, in line with expectations, while vaccine revenue is forecast at GBP 2.61 billion.

The forecast also points to clear internal contrasts. HIV revenue is expected at GBP 2.14 billion, or 0.93 percent above the GBP 2.12 billion comparison implied by RBC's one-percent description, while Nucala revenue is forecast at GBP 623 million and Shingrix sales at GBP 800 million. RBC expects full-year revenue growth of 4 percent to 5 percent and core earnings growth of 7 percent to 8 percent, according to Yahoo Finance.

Three events shape the story

On July 28, 2026, GSK reported GBP 8.41 billion in revenue for the quarter ended June 30, according to Markets Insider. On September 15, 2026, Berenberg raised its GSK target from GBp 2,000 to GBp 2,200, according to InsiderTrades. On October 13, 2026, RBC retained its GBp 1,975 target, as reported by Yahoo Finance.

What comes next for GSK?

The next dated catalysts are a US regulatory decision on bepirovirsen on October 26, 2026, an oncology investor update on October 27, 2026, and GSK's third-quarter results on October 28, 2026, according to Yahoo Finance.

What does the target imply?

RBC's GBp 1,975 target stands 11.52 percent above the GBp 1,771 share price cited when its note was published. That gap leaves the third-quarter figures, vaccine pricing and HIV execution as the main tests for the rating.